Possible leukemogenic potential of temozolomide

Pediatric Blood and Cancer

Volumn 52, Issue 4, 2009, Pages 553-

  Weiss, Brian ^a   Geiger, Hartmut ^a   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLOPHOSPHAMIDE; GENOMIC DNA; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA; DRUG DERIVATIVE;

BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RISK; GENE FREQUENCY; GENE MUTATION; IN VIVO CULTURE; LETTER; LEUKEMIA; LEUKEMOGENESIS; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MOUSE; MUTATION; NOTE; SECOND CANCER; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW CELLS; DACARBAZINE; DNA; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION;

EID: 62449130130     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21865     Document Type: Letter

References (5)

1. Kushner BH, Laquaglia MP, Kramer K, et al. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: Possible leukemogenic role of temozolomide. Pediatr Blood Cancer 2008;51: 552-554.
2. Geiger H, Schleimer D, Nattamai KJ, et al. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 2006;107:3010- 3011.
3. Vijg J, Dolle ME, Martus HJ, et al. Transgenic mouse models for studying mutations in vivo: Applications in aging research. Mech Ageing Dev 1997;99:257-271.
4. De Vita S, De Matteis S, Laurenti L, et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005;84: 760-762.
5. Su YW, Chang MC, Chiang MF, et al. Treatment-related myelodys- plastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005;71:315-318.